Pfizer's Bosulif set for EU approval in CML
This article was originally published in Scrip
The EU's CHMP has recommended that Pfizer's oral Bcr-Abl kinase inhibitor bosutinib (Bosulif 100mg and 500mg) be granted conditional marketing authorisation for the treatment of chronic myelogenous leukaemia (CML).
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.